Q3 2024 Akebia Therapeutics Inc Earnings Call Transcript
Key Points
- Akebia Therapeutics Inc (AKBA) is preparing for the U.S. market availability of Vafseo, expected in January 2025, with significant progress on launch initiatives.
- The company has secured TDAPA reimbursement from CMS and received HCPCS codes, facilitating reimbursement processes for dialysis organizations.
- Akebia has established commercial supply contracts covering approximately 60% of dialysis patients, with a goal to secure coverage for nearly 100% by the end of the year.
- The company is conducting the VOICE trial to generate important clinical data, aiming to support Vafseo utilization and potentially expand its market.
- Akebia has a strong financial position with $43.7 million in cash and cash equivalents, providing at least two years of cash runway post-Q3 2024.
- Total revenue for Q3 2024 decreased to $37.4 million from $42 million in Q3 2023, primarily due to a reduction in AURYXIA net product revenue.
- The company reported a net loss of $20 million in Q3 2024, compared to a net loss of $14.5 million in Q3 2023, partly due to non-cash interest expenses.
- There is uncertainty regarding the introduction of generic versions of AURYXIA, which could impact revenue levels.
- The company faces challenges in expanding Vafseo's label to non-dialysis patients, requiring further regulatory interactions and clinical work.
- SG&A expenses increased to $26.5 million in Q3 2024 from $22.7 million in Q3 2023, driven by pre-launch activities for Vafseo.
Good day. And thank you for standing by. Welcome to the Akebia's third quarter, 2024 financial results conference call at this time. (Operator Instructions)
now I'd like to hand the conference over to your speaker today. Mercedes Carrasco, Senior Director of Investor Relations. Please go ahead.
Thank you and welcome to Akebia's third quarter, 2024 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, November 7th, detailing our third quarter financial results. And that release is available on the investor section of our website for your convenience.
A replay of today's call will also be available on our website after we conclude. Joining me today, we have
John Butler Chief Executive Officer, Nicholas Grund, Chief Commercial Officer and
President, Chief Executive Officer & Director Erik John Ostrowski, chief Financial and Business Officer.
I'd like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
